Why the study?
Does percutaneous hemodynamic support with Impella 2.5 improve safety and hemodynamics compared to pharmacological agents alone during scar-related ventricular tachycardia ablation in patients with severe left ventricular dysfunction?
Does percutaneous hemodynamic support with Impella 2.5 improve safety and hemodynamics compared to pharmacological agents alone during scar-related ventricular tachycardia ablation in patients with severe left ventricular dysfunction?
Impella 2.5 support during scar-related VT ablation in patients with severe LV dysfunction is safe, feasible, and provides better hemodynamic support than pharmacological agents alone.
Hypothesis-generating for pLVAD in scar VT ablation; leaves open randomized comparison to pharmacological support alone.
In a consecutive series of patients with severe left ventricular dysfunction, pLVAD-supported scar VT ablation was safe and feasible. During fast simulated VT, a miniaturized axial flow pump imparted a more favorable hemodynamic profile compared with pharmacological agents alone. Cerebral oximetry is a complimentary monitoring modality during scar VT ablation, and avoidance of cerebral desaturations below a threshold of 55% may safely guide the duration of mapping during unstable VT.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2012) studied this question.